Skip to main content
Category

News Archive

Silence-Therapeutics-logo

Silence Therapeutics strengthens Board and leadership team – PharmaTimes

By News Archive

Silence-Therapeutics-logo

Silence Therapeutics has appointed Dave Lemus to its Board as non-executive director and Richard Jenkins as head of clinical development. Dave has over 20 years of US and international business experience in the pharmaceutical and biotechnology industries, having served in executive management and non-executive board roles in multiple US and European private and publicly-traded companies. He is currently executive vice chair, chief operating officer and CFO of Proteros biostructures. He also currently serves as a non-executive board member of BioHealth Innovation, Sorrento Therapeutics, and the MIT Club of Washington DC.

Read More
vaksea-logo

Iowa AgriTech Accelerator Announces Class of 2018 – Successful Farming

By News Archive

vaksea-logo

The second annual Iowa AgriTech Accelerator has chosen five start-up companies to participate in its 2018 program. These innovators will spend 100 days in Des Moines, Iowa, working with mentors in the AgTech industry who will help them with their business plan and making contacts that could help with funding, distribution, etc. They will also receive $40,000 in funding from the program’s sponsors.

Read More
martine-rothblatt-fortune-live-media-flickr

How CEO Martine Rothblatt Turns Moonshots Into Earthshots

By News Archive

martine-rothblatt-fortune-live-media-flickr

From cofounding Sirius Satellite Radio to launching a biotech company to find a cure for her daughter’s illness, Martine Rothblatt has had so much career success that any one of her accomplishments would be a crowning achievement for another entrepreneur. “I always try to convert a moonshot into an earthshot,” Rothblatt told hundreds at the Forbes Women’s Summit on Tuesday.

Read More
casi-pharmaceutical-logo

CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling

By News Archive

casi-pharmaceutical-logo

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces a strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical Co., Ltd. for the manufacturing of entecavir and cilostazol. Yiling Wanzhou International Pharmaceutical Co., Ltd. is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd. The contracted manufacturing facilities have been inspected by both the U.S. Food and Drug Administration (FDA) and China FDA (CFDA) and operate to strict International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Manufacturing Practice (GMP) standards, which will enable CASI to eventually sell both entecavir and cilostazol in the U.S., China and worldwide markets. Entecavir and cilostazol are part of the 29 abbreviated new drug applications (ANDAs) that CASI acquired from Sandoz in January 2018.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.